Malignant Female Reproductive System Neoplasm

Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,464
Recruiting: 821
Ph III recruiting: 96
Growth YoY: +6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (740)

clinicaltrialsPublishedShowing 1–50 of 51 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05611931	Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma(XPORT-EC-042)	active not recruiting	Phase 3	257	Karyopharm Therapeutics IncINDUSTRY	17	Sep 30, 2026	clinicaltrials
NCT02446600	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 3	579	National Cancer Institute (NCI)